A Phase I double-blind randomized single-dose two period crossover euglycemic clamp study to demonstrate equivalence in the PK and PD properties of BioGenomics Insulin Aspart and NovoRapid and to assess safety and tolerability in healthy male subjects
Latest Information Update: 13 Nov 2019
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Biogenomics
- 09 Oct 2017 Status changed from recruiting to completed.
- 30 Aug 2016 New trial record